



PROXIMAGEN GROUP PLC
("Proximagen" or "the Company")

Proximagen hosts European Investor Seminar in London

London, UK, 9 November 2010 – Proximagen Group plc (AIM: PRX), the rapidly growing company with a focus on diseases of the central nervous system, is today hosting a seminar for European investors in London. The event will focus on Proximagen's pipeline and business model and will provide investors with an update on the current business as Proximagen emerges as a patient-focused biopharmaceutical leader. Information will be presented by Peter Allen, Chairman; Ken Mulvany, CEO; Jackie Hunter, NED; and Tom Burke, Vice President of Commercialisation Operations at Upsher-Smith.

No new material information will be disclosed at today's investor seminar.

For further information, please contact:

Proximagen Group plc

Kenneth Mulvany, Chief Executive Officer
James Hunter, Finance Director

Tel: +44 (0)20 7400 7700

M:Communications

Mary-Jane Elliott, Emma Thompson, Amber Bielecka

Tel: +44 (0)20 7920 2330

About Proximagen

Proximagen is a rapidly growing company with a broad portfolio of novel small molecule drug candidates in development targeting disorders of the central nervous system, inflammation and oncology. Proximagen has a strong balance sheet and raised £50 million from leading international institutional investors in June 2009 to acquire and develop healthcare assets.

Proximagen is evolving to become a patient focused European biopharmaceutical leader and has plans for substantial future growth via its "science-first" and risk-mitigation strategies. When acquiring programmes, all of which are carefully vetted, the Company seeks to balance financial and scientific risk as it develops a pipeline of pre-clinical and clinical stage compounds using its drug development expertise.

Proximagen takes a flexible approach to how far it develops programmes before partnering, being mindful of a number of factors including development risk, its financial position and its belief that the retention of rights to certain territories is an important long-term value driver. For more information, please visit the Company's website at www.proximagen.com.